Vericel Corporation is a biotechnology company that focuses on developing and commercializing innovative, cell-based products for a variety of medical needs
Specializing in regenerative medicine, Vericel primarily addresses the treatment of diseases and conditions affecting the skin and cartilage. Their flagship products are designed to enhance healing and improve patient outcomes, particularly in areas such as sports medicine and burn care. Through its commitment to research and development, Vericel aims to transform the treatment landscape for patients with complex medical needs.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.